Iovance Biotherapeutics is trading 4.03% lower at $13.58, with no clear company-specific announcement identified to explain the October 6 move.

  • Supplied price context shows the decline from the October 5 close of $14.15.
  • Recent coverage focused on the raised 2026 revenue outlook and analyst price-target changes, but predates this session and does not establish a reason for the decline.
  • The broader market is higher, so the provided market context does not explain the move.